Eseherichia coli are the main causative agents of uncomplicated urinary tract infection (UTI) and account for >85% of cases of acute cystitis and pyelonephritis, >60% of recurrent cystitis, and at least 35% of recurrent pyelonephritis [1]. The reservoir for uropathogenic E. coli is fecal flora, from which bacteria spread to the urogenital mucosa, ascend into the bladder, and adhere to bladder epithelium. Once established in the bladder, the bacteria multiply and establish a local infection (cystitis) and may further ascend to involve the ureters and kidneys (pyelonephritis). While many factors contribute to the acquisition and progression of E. coli UTI, colonization of the urogenital tract by pathogenic bacteria appears to be a prerequisite for disease [2]. One promising strategy for the prevention of UTI is the development of a vaccine that targets the mechanism(s) by which uropathogens adhere to bladder epithelial cells.